Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

F Trémolières1, R Garraffo, O Lortholary

  • 1Service de médecine interne, hôpital François-Quesnay, 78200 Mantes-la-Jolie, France.

Medecine Et Maladies Infectieuses
|November 1, 2005
PubMed
Summary
This summary is machine-generated.

The golden age of antibiotics has passed, leading to challenges in developing new antibacterial drugs. This study proposes novel strategies to optimize future drug development against emerging bacterial resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tuberculosis after allogeneic hematopoietic stem cell transplantation: a decade nationwide case-control retrospective study in low-incidence country.

Bone marrow transplantation·2026
Same author

Determinants of radiological patterns and severity in immunocompromised adults with Metapneumovirus infection.

Respiratory medicine·2024
Same author

[Pulmonary complications of Chronic Granulomatous Disease].

Revue des maladies respiratoires·2024
Same author

[Screening and prevention of toxic optic neuropathies due to anti-mycobacterium therapies: proposal of recommendations].

Journal francais d'ophtalmologie·2022
Same author

Cerebral aspergillosis in the era of new antifungals: The CEREALS national cohort study Nationwide CEREbral Aspergillosis Lesional study (CEREALS).

The Journal of infection·2021
Same author

Combined High-Dose Caspofungin and Liposomal Amphotericin B for Treatment of Azole-Resistant Cerebral Aspergillosis.

Antimicrobial agents and chemotherapy·2021
Same journal

[Etiology and clinical expression of angina].

Medecine et maladies infectieuses·2024
Same journal

[Rational use of antibiotics treatment in acute bronchitis].

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
Same journal

[Detection of human rotaviruses in faeces : comparison of five methods].

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
Same journal

Medecine et maladies infectieuses·2024
See all related articles

Area of Science:

  • Microbiology and Infectious Diseases
  • Pharmaceutical Sciences
  • Drug Development

Background:

  • The period from 1941 to the 1990s is recognized as the golden age of antibacterial antibiotics.
  • Significant challenges arose in the late 20th century, with many potential antibacterial molecules failing to reach the market or facing prescription difficulties.

Purpose of the Study:

  • To address the declining efficacy of current antibiotics and the rise of bacterial resistance.
  • To propose innovative approaches for optimizing the development of future antibacterial drug molecules.

Main Methods:

  • Analysis of historical trends in antibiotic development.
  • Identification of limitations in current drug development systems.
  • Formulation of new conceptual strategies for future drug discovery.

Related Experiment Videos

Main Results:

  • The golden age of antibiotics yielded numerous compounds, but market entry and clinical adoption proved difficult for many.
  • Current systems for drug development have reached their limitations in combating evolving bacterial resistance.
  • The study outlines three distinct propositions for optimizing the development of novel antibacterial agents.

Conclusions:

  • Anticipating and managing future bacterial resistance is a critical imperative.
  • New conceptual frameworks are essential for developing drugs effective against resistant bacteria.
  • Optimizing current systems and embracing novel approaches are key to securing future antibacterial therapies.